Replies to post #4299 on Biotech Values

[bladerunner1717]

Ferris, Baker Watts, Inc. (GNVC)
E-mail or Print this story

11 November 2004, 10:28am ET

GNVC: Upgrade to Buy - GenVec will be advised to carefully monitor all patients being treated with TNFerade for the potential development of blood clot formation. In patients with esophageal cancer, TNFerade will be permitted to be studied at doses at which abnormal clotting was not observed. In our opinion, the company should be permitted to continue its scheduled development of TNFerade without significant interruption. We imagine that the FDA should provide GenVec with its guidance within several weeks of receipt of the company`s official response.

Click below to read more about subscribing to the full JAGnotes product.

http://www.jagnotes.com/c/23/98.cfm?pagetitle=SubscribeNow Copyright 2004 JAGfn.com All Rights Reserved
E-mail this story Print this story

Ferris makes it sound like they've seen the FDA response to GNVC. Awfully positive when GNVC hasn't even responded to the FDA yet.

What do you all think? PGS?

Bladerunner